This test uses RT-qPCR technology to detect the expression of 16 tumor-related genes (including those associated with proliferation, invasion, HER2, and hormone signaling) and 5 reference genes. It quantifies the test results into a Recurrence Score (RS) to predict 10-year long-term recurrence risk and chemotherapy benefit. This test can aid in the development of breast cancer treatment plans and help avoid undertreatment or overtreatment.